Steven Plymale, president and COO of Profound Medical (TSX-V:PRN), has been appointed an independent director of XOR-Labs, a spinoff from Toronto General Hospital at University Health Network, the world’s leading center for lung transplantation and a MaRS Innovation company.
Mr. Plymale has a strong record of building medical technologies from the critical early stages of product development through operational scale-up, and clinical and regulatory pathway development.
Profound is commercializing a real-time MRI-guided thermal ultrasound ablation treatment for prostate disease, known as TULSA-PRO.
In a statement, Mr. Plymale said XOR has the potential to change the critical field of organ transplantation. Mr. Plymale will be joining leading lung transplant clinicians such as Dr. Shaf Keshavjee, and key sector leaders such as Dr. Georg Matheis, CEO of Xenios, a global leader in innovative solutions for heart and lung failure.
Dr. Tom Waddell, CEO of XOR, said XOR plans to continue to add high-quality individuals to its team to help achieve both its short- and long-term objectives.
